SG HealthCare Co Ltd

SG HealthCare Co Ltd reported a revenue of 1,968,778,250 KRW in the latest period. Despite this, the company recorded a net loss of 612,978,520 KRW and an operating loss of 761,197,770 KRW, indicating significant financial distress. The company's operating cash flow was positive at 146,064,720 KRW, but its free cash flow was negative at -568,897,390 KRW, suggesting that the company is not generating sufficient cash to fund its operations and capital expenditures. The company's liquidity risk could not be assessed due to the lack of balance-sheet inputs and no going-concern language in the source documents.

The company's profitability metrics are concerning. The gross profit margin is 25.66% (505,085,550 KRW / 1,968,778,250 KRW), which is below the industry median for medical equipment and supplies. The operating margin is -38.66% (-761,197,770 KRW / 1,968,778,250 KRW), and the net margin is -31.14% (-612,978,520 KRW / 1,968,778,255 KRW), both of which are significantly negative. These metrics suggest that the company is not only failing to cover its operating expenses but is also incurring substantial losses after all expenses, including taxes and interest.

SG HealthCare Co Ltd's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. The company's geographic exposure is not disclosed, but given its listing on the Korean market, it is likely focused on the domestic market. The lack of segmental and geographic diversification increases the company's exposure to regional economic and regulatory risks.

The company's growth trajectory is uncertain. The available data does not provide historical revenue figures or forward-looking guidance, making it difficult to assess the company's growth potential. The negative operating and net income suggest that the company is not on a sustainable growth path and may require significant restructuring or external financing to continue operations.

The company's risk profile is high, primarily due to its liquidity risk, which could not be assessed. The lack of balance-sheet inputs and no going-concern language in the source documents indicates a lack of transparency and potential financial instability. The dilution risk is currently low, but the company's negative free cash flow and operating losses may necessitate future equity or debt financing, which could lead to dilution for existing shareholders.

Recent events and filings do not provide additional insights into the company's financial health or strategic direction. The absence of recent transcripts or filings suggests a lack of public disclosure, which is a red flag for investors. The company's financial performance and risk profile indicate that it is in a precarious position and may require significant intervention to stabilize its operations.